Relevante Biomarker in der Infektiologie

Ein Biomarker in der Infektiologie sollte idealerweise eine Infektion mit hoher Sensitivität und Spezifität von einer durch andere Ursachen hervorgerufenen Inflammation unterscheiden. Er sollte außerdem zur Überwachung der klinischen Reaktion und zur Feststellung der Behandlungsdauer einsetzbar sein. Dieser Beitrag beleuchtet, inwieweit das C-reaktive Protein und Procalcitonin diese Anforderungen erfüllen und berichtet von der Suche nach weiteren Biomarkern – u.a. mithilfe „Omics“-basierter Technologien und Einbindung Künstlicher Intelligenz.

Abstract

A biomarker in infectiology should ideally be able to identify infectious agents, monitor clinical response and determine the duration of treatment. This article answers the question to what extent C-reactive protein and procalcitonin meet these requirements and reports on the search for further biomarkers – e.g. with the help of “omics”-based technologies and the integration of artificial intelligence.

Schlüsselwörter

Biomarker - Infektionskrankheiten - Sepsis - C-reaktives Protein - Procalcitonin - Omics-basierte Technologien

Keywords

biomarkers - infectious diseases - sepsis - C-reactive protein - procalcitonin - omics-based technologies

• Literatur

• 1 Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood) 2018; 243: 213-221
• 2 FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US);. 2016
• 3 Shearer WT, Buckley RH, Engler RJ. et al. Practice parameters for the diagnosis and management of immunodeficiency. The Clinical and Laboratory Immunology Committee of the American Academy of Allergy, Asthma, and Immunology (CLIC-AAAAI). Ann Allergy Asthma Immunol 1996; 76: 282-294
• 4 Barichello T, Generoso JS, Singer M. et al. Biomarkers for sepsis: more than just fever and leukocytosis – a narrative review. Crit Care 2022; 26: 14
• 5 Conti B, Tabarean I, Andrei C. et al. Cytokines and fever. Front Biosci 2004; 9: 1433-1449
• 6 Zandstra J, Jongerius I, Kuijpers TW. Future biomarkers for infection and inflammation in febrile children. Front Immunol 2021; 12: 631308
• 7 Karakioulaki M, Stolz D. Biomarkers in pneumonia – beyond procalcitonin. Int J Mol Sci 2019; 20: 2004
• 8 Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature. Pharmacotherapy 2018; 38: 569-581
• 9 Matwiyoff GN, Prahl JD, Miller RJ. et al. Immune regulation of procalcitonin: a biomarker and mediator of infection. Inflamm Res 2012; 61: 401-409
• 10 Ehler J, Busjahn C, Schürholz T. Welche Biomarker zu Diagnosestellung und Steuerung der antiinfektiven Therapie bei Sepsis?. Der Anaesthesist 2022; 71: 3-11
• 11 Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. eBioMedicine 2022; 86: 104363
• 12 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-810
• 13 Evans L, Rhodes A, Alhazzani W. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49: e1063-e1143
• 14 Kalantar KL, Neyton L, Abdelghany M. et al. Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults. Nat Microbiol 2022; 7: 1805-1816
• 15 Pierrakos C, Velissaris D, Bisdorff M. et al. Biomarkers of sepsis: time for a reappraisal. Crit Care 2020; 24: 287
• 16 Miller WD, Keskey R, Alverdy JC. Sepsis and the microbiome: a vicious cycle. J Infect Dis 2021; 223 (12) S264-S269
• 17 Komorowski M, Green A, Tatham KC. et al. Sepsis biomarkers and diagnostic tools with a focus on machine learning. EBioMedicine 2022; 86: 104394
• 18 Strimbu K, Tavel JA. What are biomarkers?. Curr Opin HIV AIDS 2010; 5: 463-466
• 19 Bach B. Leitlinie bei ambulant erworbener Pneumonie. CME 2022; 19: 14-15